Related Experiment Videos
Vascular endothelial growth factor gene polymorphisms in giant cell arteritis
Luigi Boiardi1, Bruno Casali, Davide Nicoli
1Servizio di Reumatologia and Laboratorio di Biologia Molecolare, Azienda Ospedaliera Arcispedale S. Maria Nuova, Viale Umberto 1 N50, 42100 Reggio Emilia, Italy.
The Journal of Rheumatology
|October 7, 2003
Summary
Genetic variations in vascular endothelial growth factor (VEGF) are linked to giant cell arteritis (GCA) susceptibility. Specifically, C634 and I alleles increase the risk of developing GCA, but not ischemic complications.
Area of Science:
- Genetics
- Immunology
- Rheumatology
Background:
- Giant cell arteritis (GCA) is a large-vessel vasculitis with potential for severe ischemic complications.
- Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and vascular inflammation.
Purpose of the Study:
- To investigate the association between VEGF gene polymorphisms and susceptibility to GCA.
- To explore the relationship between VEGF polymorphisms and GCA disease expression, including ischemic complications.
Main Methods:
- Genotyping of 92 GCA patients and 200 controls for VEGF promoter polymorphisms (936 C/T, 634 C/G, 18 bp I/D).
- Analysis of allele and genotype frequencies in GCA patients versus controls.
- Investigated in vitro VEGF release from peripheral blood mononuclear cells (PBMCs).
Main Results:
- Significantly higher carriage rates of the I allele (18 bp insertion) and C634 allele in GCA patients compared to controls.
- No significant differences in polymorphism distribution between GCA patients with and without ischemic complications.
- Higher LPS-stimulated VEGF production in homozygous II individuals compared to DD individuals.
Conclusions:
- The C634 and I alleles of the VEGF gene are associated with an increased susceptibility to developing GCA.
- VEGF gene polymorphisms do not appear to influence the risk of ischemic complications in GCA patients.